Harnessing the natural machinery of the lysosome

Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society.

We are establishing ourselves at the forefront of protein degradation. Through our novel, proprietary platform, we are building a broad pipeline of oral small molecule degraders of extracellular pathogenic proteins.

Targeted protein degradation is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. While proteolysis-targeting chimera (PROTAC) protein degraders have revolutionised the field of targeted protein degradation, it is limited to intracellular disease proteins.

The only small molecule extracellular degrader platform with broad disease applicability

At Draupnir, our differentiated platform technology is enabling the development of protein degraders that target extracellular disease proteins, with potential to target 40% of the human proteome and offering broad disease applicability across multiple areas of unmet therapeutic need.

Our team at Draupnir Bio is driven by a deep commitment to scientific excellence, and by the desire to bring innovative therapies to patients.